| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Improved survival with ipilimumab in patients with metastatic melanoma. | N Engl J Med | 2010 | 67.34 |
| 2 | Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. | J Clin Oncol | 2005 | 9.72 |
| 3 | A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. | Invest New Drugs | 2010 | 2.09 |
| 4 | Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. | J Immunother | 2006 | 1.66 |